PT3580220T - Aminotriazolopiridinas como inibidores de quinase - Google Patents
Aminotriazolopiridinas como inibidores de quinaseInfo
- Publication number
- PT3580220T PT3580220T PT187074984T PT18707498T PT3580220T PT 3580220 T PT3580220 T PT 3580220T PT 187074984 T PT187074984 T PT 187074984T PT 18707498 T PT18707498 T PT 18707498T PT 3580220 T PT3580220 T PT 3580220T
- Authority
- PT
- Portugal
- Prior art keywords
- aminotriazolopyridines
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762458144P | 2017-02-13 | 2017-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3580220T true PT3580220T (pt) | 2022-01-03 |
Family
ID=61283335
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT187074984T PT3580220T (pt) | 2017-02-13 | 2018-02-12 | Aminotriazolopiridinas como inibidores de quinase |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US10913738B2 (enExample) |
| EP (1) | EP3580220B1 (enExample) |
| JP (1) | JP7097373B2 (enExample) |
| KR (1) | KR102549952B1 (enExample) |
| CN (1) | CN110520423B (enExample) |
| AU (1) | AU2018217488B2 (enExample) |
| BR (1) | BR112019016635A2 (enExample) |
| CA (1) | CA3053484A1 (enExample) |
| CY (1) | CY1124978T1 (enExample) |
| DK (1) | DK3580220T3 (enExample) |
| EA (1) | EA039808B1 (enExample) |
| ES (1) | ES2902676T3 (enExample) |
| HR (1) | HRP20212000T1 (enExample) |
| HU (1) | HUE057801T2 (enExample) |
| IL (1) | IL268614B (enExample) |
| LT (1) | LT3580220T (enExample) |
| MA (1) | MA47460A (enExample) |
| MX (1) | MX378515B (enExample) |
| PL (1) | PL3580220T3 (enExample) |
| PT (1) | PT3580220T (enExample) |
| RS (1) | RS62801B1 (enExample) |
| SG (1) | SG11201907335UA (enExample) |
| SI (1) | SI3580220T1 (enExample) |
| SM (1) | SMT202200001T1 (enExample) |
| WO (1) | WO2018148626A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3580220B1 (en) * | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| KR102662197B1 (ko) * | 2017-10-30 | 2024-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노이미다조피리다진 |
| JP7307734B2 (ja) | 2018-01-26 | 2023-07-12 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのアミノピロロトリアジン |
| AU2019301628C1 (en) | 2018-07-09 | 2025-02-06 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting NaV1.8 |
| WO2020014243A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | PYRIDAZINE COMPOUNDS FOR INHIBITING Nav1.8 |
| CA3112519A1 (en) | 2018-09-13 | 2020-03-19 | Bristol-Myers Squibb Company | Indazole carboxamides as kinase inhibitors |
| AU2019337612A1 (en) | 2018-09-13 | 2021-05-13 | Bristol-Myers Squibb Company | 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1) |
| CN113166116B (zh) * | 2019-01-25 | 2022-12-27 | 北京赛特明强医药科技有限公司 | 酰胺基桥连杂环类化合物、及其组合物与应用 |
| US20220177462A1 (en) * | 2019-03-22 | 2022-06-09 | Genfleet Therapeutics (Shanghai) Inc. | Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof |
| JP7600228B2 (ja) | 2019-10-03 | 2024-12-16 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのインダゾールカルボキサミド |
| JP7441477B2 (ja) * | 2020-02-13 | 2024-03-01 | ▲勁▼方医▲薬▼科技（上海）有限公司 | ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用 |
| CN114230565B (zh) * | 2020-09-09 | 2023-10-27 | 成都奥睿药业有限公司 | 5-取代吲哚3-酰胺衍生物及其制备方法和用途 |
| CN114262322B (zh) * | 2020-09-16 | 2026-01-06 | 中国科学院上海有机化学研究所 | 一类细胞程序性坏死抑制剂及其制备方法和用途 |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
| TWI824626B (zh) * | 2021-08-02 | 2023-12-01 | 大陸商勁方醫藥科技(上海)有限公司 | Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型 |
| IL308349A (en) | 2021-08-10 | 2024-01-01 | Abbvie Inc | NICOTINAMIDE RIPK1 INHIBITORS |
| TW202345852A (zh) | 2022-03-16 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠雜環類化合物、其製備方法及其在醫藥上的應用 |
| CN114989079B (zh) * | 2022-06-21 | 2023-06-23 | 中国药科大学 | Ripk1激酶靶点抑制剂及其医药用途 |
| AR131541A1 (es) | 2023-01-07 | 2025-04-09 | Syngenta Crop Protection Ag | Compuestos de carboxamida novedosos |
| WO2025072395A1 (en) * | 2023-09-27 | 2025-04-03 | Bristol-Myers Squibb Company | Triazolopyridinyl compounds as kinase inhibitors |
| WO2025109114A1 (en) | 2023-11-24 | 2025-05-30 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149637A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2025149629A1 (en) | 2024-01-12 | 2025-07-17 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
| WO2026008750A1 (en) | 2024-07-05 | 2026-01-08 | Syngenta Crop Protection Ag | Novel carboxamide compounds |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050288502A1 (en) * | 2004-06-25 | 2005-12-29 | Andersen Denise L | Substituted heterocyclic compounds and methods of use |
| MX2008012482A (es) * | 2006-03-31 | 2008-10-10 | Abbott Lab | Compuestos de indazol. |
| ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
| WO2009068482A1 (en) | 2007-11-27 | 2009-06-04 | Cellzome Limited | Amino triazoles as pi3k inhibitors |
| WO2010007100A1 (en) * | 2008-07-15 | 2010-01-21 | Cellzome Ltd | 7-substituted amino triazoles as pi3k inhibitors |
| WO2010057877A1 (en) | 2008-11-18 | 2010-05-27 | Cellzome Limited | 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors |
| US8598163B2 (en) | 2009-02-04 | 2013-12-03 | Vitae Pharmaceuticals, Inc. | Derivatives of [1,3]Oxazin-2-one useful for the treatment of metabolic diseases such as lipid disorders |
| US9783573B2 (en) | 2012-09-18 | 2017-10-10 | Bristol-Myers Squibb Company | IAP antagonists |
| TN2015000542A1 (en) | 2013-06-10 | 2017-04-06 | Bayer Pharma AG | Novel compounds for the treatment of cancer |
| CA2958645A1 (en) * | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| CN108349970B (zh) * | 2015-11-05 | 2021-03-05 | 住友化学株式会社 | 稠合杂环化合物 |
| WO2018017435A1 (en) | 2016-07-22 | 2018-01-25 | Accro Bioscience Inc. | Heteroaryl compounds as inhibitors of necrosis, composition and application thereof |
| JP7190906B2 (ja) | 2017-01-24 | 2022-12-16 | 住友化学株式会社 | 縮合複素環化合物及びそれを含有する組成物 |
| EP3580220B1 (en) * | 2017-02-13 | 2021-11-17 | Bristol-Myers Squibb Company | Aminotriazolopyridines as kinase inhibitors |
| KR102662197B1 (ko) | 2017-10-30 | 2024-04-29 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 억제제로서의 아미노이미다조피리다진 |
| JP7307734B2 (ja) | 2018-01-26 | 2023-07-12 | ブリストル－マイヤーズ スクイブ カンパニー | キナーゼ阻害剤としてのアミノピロロトリアジン |
| AR123793A1 (es) * | 2020-10-19 | 2023-01-11 | Bristol Myers Squibb Co | Compuestos de triazolopiridinilo como inhibidores de quinasas |
-
2018
- 2018-02-12 EP EP18707498.4A patent/EP3580220B1/en active Active
- 2018-02-12 MX MX2019009555A patent/MX378515B/es unknown
- 2018-02-12 SM SM20220001T patent/SMT202200001T1/it unknown
- 2018-02-12 HR HRP20212000TT patent/HRP20212000T1/hr unknown
- 2018-02-12 US US16/484,604 patent/US10913738B2/en active Active
- 2018-02-12 BR BR112019016635A patent/BR112019016635A2/pt not_active Application Discontinuation
- 2018-02-12 LT LTEPPCT/US2018/017755T patent/LT3580220T/lt unknown
- 2018-02-12 CA CA3053484A patent/CA3053484A1/en active Pending
- 2018-02-12 AU AU2018217488A patent/AU2018217488B2/en not_active Ceased
- 2018-02-12 HU HUE18707498A patent/HUE057801T2/hu unknown
- 2018-02-12 KR KR1020197026464A patent/KR102549952B1/ko active Active
- 2018-02-12 SG SG11201907335UA patent/SG11201907335UA/en unknown
- 2018-02-12 MA MA047460A patent/MA47460A/fr unknown
- 2018-02-12 JP JP2019543377A patent/JP7097373B2/ja active Active
- 2018-02-12 PT PT187074984T patent/PT3580220T/pt unknown
- 2018-02-12 DK DK18707498.4T patent/DK3580220T3/da active
- 2018-02-12 CN CN201880024064.1A patent/CN110520423B/zh active Active
- 2018-02-12 ES ES18707498T patent/ES2902676T3/es active Active
- 2018-02-12 SI SI201830511T patent/SI3580220T1/sl unknown
- 2018-02-12 EA EA201991915A patent/EA039808B1/ru unknown
- 2018-02-12 PL PL18707498T patent/PL3580220T3/pl unknown
- 2018-02-12 RS RS20220021A patent/RS62801B1/sr unknown
- 2018-02-12 WO PCT/US2018/017755 patent/WO2018148626A1/en not_active Ceased
-
2019
- 2019-08-09 IL IL268614A patent/IL268614B/en unknown
-
2020
- 2020-12-09 US US17/116,016 patent/US12157733B2/en active Active
-
2022
- 2022-01-18 CY CY20221100043T patent/CY1124978T1/el unknown
-
2024
- 2024-10-28 US US18/928,275 patent/US20250074909A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR24C1016I1 (fr) | Inhibiteurs de ret | |
| CY2024003I2 (el) | Ενωσεις χρησιμες ως αναστολεις κινασης | |
| PT3580220T (pt) | Aminotriazolopiridinas como inibidores de quinase | |
| PT3788040T (pt) | Piridazinonas como inibidores de parp7 | |
| EP3541932A4 (en) | INHIBITORS OF CRISPR-CAS9 | |
| EP3347018A4 (en) | HEMMER OF CYCLINE-DEPENDENT KINASES | |
| EP3247692A4 (en) | INHIBITORS OF TRKA KINASE | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| BR112017025542A2 (pt) | compostos de naftiridina como inibidores de quinase jak | |
| PT3209656T (pt) | Compostos de indol carboxamida úteis como inibidores de quinase | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| PT3105226T (pt) | Ciclopropilaminas como inibidores de lsd1 | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3347008A4 (en) | BETA-Lactamase INHIBITORS | |
| EP3313828A4 (en) | METALLO-BETA-Lactamase INHIBITORS | |
| DK3681884T3 (da) | Rad51-inhibitorer | |
| LT3704118T (lt) | Aminoimidazopiridazinai, kaip kinazės inhibitoriai | |
| IL269063B (en) | Pyrimidopyrimidinones used as wee-1 kinase inhibitors | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| EP3394068A4 (en) | TDO2 INHIBITORS | |
| EP3303283A4 (en) | Fto inhibitors | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| EP3600301A4 (en) | KDM4 INHIBITORS |